21 Nov 2014 07:30
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY NAME: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collagen Solutions plc (the "Company")
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Registered address:
Condor House, 10 St. Paul's Churchyard, London, EC4M 8AL
Trading address:
3 Robroyston Oval, Nova Technology Park, Glasgow, G33 1AP
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COUNTRY OF INCORPORATION: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
England & Wales
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
http://www.collagensolutions.co.uk
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Company provides customers with medical grade collagen products and development services to create collagen components from concept to clinical trial stage, including technology transfer and contract manufacturing. It is acquiring Southern Lights Ventures 2002 Limited ("Southern Lights Biomaterials") by means of a reverse takeover under Rule 14 of the AIM Rules for Companies.
Southern Lights Biomaterials was co-founded in 2003, by Geoffrey Bennett after BSE discoveries in US and Canada left a gap in the market for a New Zealand-based bovine supply chain for medical device manufacturers. It is based in the North Island of New Zealand, and benefits from the logistical advantage of being close to a readily available and consistent supply of source tissue from a country ranked by the World Organisation for Animal Health as a "negligible BSE risk" country. Southern Lights Biomaterials is a provider of processed and semi-processed biomaterials to medical device manufacturers, to an international client base. In addition, it provides consultancy services focussing on collagen, collagen related services and regulatory support to its customers.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
170,968,865 ordinary shares of 1p each at an issue price of 7p
No restrictions as to transfer of the securities.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placing of £6m. Anticipated market capitalisation on Admission: £11.97m
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20.58%
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
N/A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Directors
David Eric Evans (Chairman) Dr. Stewart White (Chief Executive Officer) Gillian Nancy Black (Chief Financial Officer) Dr. Kevin William Wilson (Non-Executive Director) Malcolm John Gillies (Non-Executive Director)
Proposed Director
Brian Geoffrey Bennett (Chief Business Officer)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
N/A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(i) 31 March (ii) 31 March 2014 (iii) 30 September 2015, 31 December 2015, 30 September 2016
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXPECTED ADMISSION DATE: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10 December 2014
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NAME AND ADDRESS OF NOMINATED ADVISER: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zeus Capital Ltd
23 Berkeley Square London W1J 6HE
82 King Street Manchester M2 4WQ
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NAME AND ADDRESS OF BROKER: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zeus Capital Ltd
23 Berkeley Square London W1J 6HE
82 King Street Manchester M2 4WQ
Panmure Gordon & Co
One New Change London EC4M 9AF UK
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
http://www.collagensolutions.co.uk
This website will contain full details about the Company and the admission of its ordinary shares to trading on AIM.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DATE OF NOTIFICATION: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
21 November 2014
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEW/ UPDATE: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
New
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||